Terminal › Stocks › PPCB

Propanc Biopharma, Inc. (PPCB) Stock

Healthcare · Biotechnology · AU

$2.00 -17.70%

Last updated Jun 18, 2026 23:50 UTC

PPCB Key Statistics

Market Cap$30.34M

P/E (TTM)-0.15

P/S (TTM)1,014.48

P/B (TTM)2.56

Revenue (TTM)$29,904.00

EPS (TTM)$-13.54

Dividend Yield—

ROE (TTM)-465.17%

Net Margin-9,999.99%

Gross Margin0.44%

52W High$6.79

52W Low$0.10

Analyst View—

Price Target—

Employees1

Volume646,065

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

CEO: James Nathanielsz. Company website

See PPCB live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open PPCB in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.